Latest Biotechnology, Pharmaceutical and Healthcare News from BioPharma-Reporter

11:56 EDT 24th September 2017 | BioPortfolio

Here are the most relevant search results for "BioPharma-Reporter" found in our extensive news archives from over 250 global news sources.

More Information about BioPharma-Reporter on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about BioPharma-Reporter for you to read. Along with our medical data and news we also list BioPharma-Reporter Clinical Trials, which are updated daily. BioPortfolio also has a large database of BioPharma-Reporter Companies for you to search.

Showing News Articles 1–25 of 1,200+ from BioPharma-Reporter

Friday 22nd September 2017

Filling and freeze-drying drivers for $950m Cook deal says Catalent

Catalent has cited Cook’s ability to make and freeze-dry liquid drugs as major drivers for its planned takeover and said it is keen to take on the firm’s biopharma customers.

Lonza says cell imaging tech monitors ‘anytime and anywhere’

Lonza has launched an updated version of its cell imaging technology, which it says has improved image capture and data transfer options, and enables researchers to monitor cells remotely. 

Robust logistics system key challenge for cell therapies, Kiadis

Kiadis Pharma says it is looking at expanding production of its blood cancer cell therapy candidate ATIR101 after receiving US FDA breakthrough designation.

Pfizer takes J&J to court for blocking US access to biosimilar Inflectra

Pfizer has accused J&J of restricting biosimilar uptake through uncompetitive practises in its efforts to maintain a monopoly for its bestselling mAb Remicade (infliximab).

Wednesday 20th September 2017

ChromaTan to develop continuous purification tech with $2.5m US FDA grant

ChromaTan will develop an integrated and continuous downstream purification platform through provisions in the 21st Century Cures Act to support manufacturing initiatives.

US FDA stem cell enforcement challenged by state legislation

State legislation allowing unapproved stem cell treatments could undermine efforts by the US FDA to clampdown on unregistered clinics.

EU distribution: BioCat on board the Vmax Express

SGI-DNA has selected BioCat to distribute its protein expression platform Vmax Express, which it says is more rapid than traditional expression systems.

Tuesday 19th September 2017

Fire ant venom to combat thick skin

Researchers say compounds from fire ant venom could be used to develop psoriasis treatments which limit skin-thickening side effects.

Catalent to buy Cook Pharmica for $950m in cash

Catalent Inc has announced it will buy Cook Pharmica for $950m (€792m) in cash to boost its high tech drug production business.

Samsung Bioepis will use CMOs to make Ontruzant if it is approved

Samsung Bioepis will use contractors to make its candidate Herceptin biosimilar Ontruzant if it goes on to be approved in Europe.

Bayer takes a shine to Berkeley Light's Beacon biologics workflow tech

Bayer has signed a deal to use Berkeley Lights’ automated biological workflow platform for cell line development and antibody discovery.

Synpromics expansion to support growing gene control business

Moving to a larger facility will help Scottish firm Synpromics Ltd increase its gene control and cell line services presence, the firm says.

Friday 15th September 2017

US FDA approves Amgen and Allergan's Avastin biosimilar

US regulators have approved Amgen Inc’s Mvasi (bevacizumab-awwb), a biosimilar version of Roche’s monoclonal antibody (mAb) cancer treatment Avastin (bevacizumab). 

Remicade biosimilar: J&J’s ‘fear and loathing’ subdued as Pfizer slugs it out

Fears of Remicade competition have not manifested in significant growth declines for Johnson & Johnson, but Pfizer says US payers and physicians are slowly getting comfortable with biosimilars.

Thursday 14th September 2017

Kaneka Eurogentec to build biodrug production plant in Belgium

Kaneka Eurogentec has announced plans to build a biopharmaceutical manufacturing facility in Seraing, Belgium.

Microtissue magic: 3D-printed tech for cell culture production 'degrades on demand'

Researchers at Brown University have developed a 3D printing technique which they say could be used to make cell cultures for biopharmaceutical production.

Momenta: WuXi single-use capacity expansion to support changing biosimilar demand

Momenta says flexibility built into its contract with WuXi Biologics will offset fluctuations in demand for Chinese biosimilars.

Wednesday 13th September 2017

Fujifilm Diosynth Biotechnologies opens new UK lab

Fujifilm Diosynth Biotechnologies has opened a $9m process development laboratory in Teeside, UK.

Tuesday 12th September 2017

Biocon says Malaysia insulin plant passed HPRA inspection

Biocon says its insulin plant in Malaysia has been awarded a European GMP certificate after an inspection by Ireland’s Health Products Regulatory Authority (HPRA).

Expression yourself: Win an iPad in our bioprocessing survey

Is plastic fantastic? Is stainless still à la mode*? Do Chinese hamsters continue to tow the cell line? Biopharma-Reporter wants your opinions for its second annual biomanufacturing survey.

Friday 8th September 2017

Merck boosts cancer pipeline in €464m deal

Merck & Co has announced it will acquire immunotherapy-focused Rigontec and lead candidate RGT100, designed to treat patients with solid tumours and lymphoma.

CGT Catapult teams with TrakCel for cell and gene therapy tracking

Firms that make therapies at the Cell and Gene Therapy Catapult facility in Stevenage, UK will track their products using tech provided by TrakCel.

Lilly preserves biomanfacturing network amid $500m cost-saving restructure

Eli Lilly has announced a restructuring plan which will cut around 3,500 jobs but biomanufacturing will remain largely unaffected.

Thursday 7th September 2017

Celltrion confident in quality of biosimilar supply despite US FDA 483

Celltrion Inc has received a FDA Form 483 with 12 observations but remains confident no exported biosimilar products have any quality issues.

Wednesday 6th September 2017

GE launches cell therapy thawing tech

GE Healthcare has launched a thawing technology for cell therapies it says removes the risks and inconsistencies of standard water baths.

Quick Search

News Quicklinks